Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company is headquartered in South San Francisco, California.
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-265.79M |
| Operating Margin | 0.00% |
| Return on Equity | -20.20% |
| Return on Assets | -14.90% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $19.02 |
| Price-to-Book | 1.89 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | -13.46 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $71.31M |
| Float | $54.64M |
| % Insiders | 2.85% |
| % Institutions | 97.78% |
Volatility is currently contracting
LLY's GLP-1 momentum, Foundayo launch and retatrutide pipeline support growth, but premium valuation and rising competition weigh on the stock.
Structure Therapeutics Inc. (GPCR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Structure Therapeutics remains a Strong Buy, with recent data de-risking its lead oral obesity drug, aleniglipron. Aleniglipron's 72-week open-label data showed 16.2% weight loss, low AE discontinuations, and no DILI, though Phase 3 efficacy and safety monitoring remain key. ACCG-2671, an oral amylin agonist, now has human data and offers potential for combination therapy, further differentiating GPCR's pipeline.
NVO's semaglutide cuts BMI in children with obesity in phase III study, with 40.4% no longer classified as having obesity after 68 weeks.
ACCG-2671 (oral small molecule amylin receptor agonist) demonstrated a ~6-day half-life, no serious adverse events, and evidence of target engagement including up to 3.3% body weight loss in Phase 1/2a SAD clinical trial First participants dosed with ACCG-2671 in the 12-week MAD portion of the Phase 1/2a clinical trial; topline data expected in 1H 2027 Aleniglipron (oral small molecule selective GLP-1 receptor agonist) demonstrated up to 16.2% mean reduction in body weight at 72 weeks with no observed plateau, and improved tolerability with a 2.5 mg starting dose, including less than 5% study-drug discontinuation rates due to adverse events in the ACCESS OLE clinical trial ACCOMPLISH-1 and ACCOMPLISH-2 registrational Phase 3 clinical trials for aleniglipron enrollment ongoing; topline data expected in 2H 2028 Company to host conference call today at 8:30 a.m. ET SAN FRANCISCO, Sept.
SAN FRANCISCO, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today announced that management will participate in three upcoming healthcare conferences in September: 2026 Cantor Global Healthcare Conference Date: Thursday, September 10Format: Fireside chat and 1x1 meetingsTime: 3:55 – 4:25 PM EDTLocation: New York, NY Morgan Stanley 24 th Annual Global Healthcare Conference Date: Wednesday, September 16Format: Fireside chat and 1x1 meetingsTime: 10:45 – 11:20 AM EDTLocation: New York, NY Bernstein's 3rd Annual Healthcare Forum Date: Wednesday, September 23Format: Fireside Chat and 1x1 meetingsTime: 3:00 – 3:40 PM EDTLocation: New York, NY The live and archived webcasts will be accessible from the company's website at https://ir.structuretx.com/events-presentations/events and replays will be available for at least 90 days.
Novo Nordisk and Structure Therapeutics are taking different paths in the obesity market, from a global GLP-1 leader to a clinical-stage challenger with oral therapies.
Structure Therapeutics (GPCR) maintains a Buy rating, driven by strong Phase 2b data for its oral GLP-1 candidate aleniglipron targeting obesity. Aleniglipron demonstrated up to 16.2% weight loss at 44 weeks, a favorable discontinuation rate, and is now in Phase 3 studies with pivotal data expected Q4 2028. GPCR's $1.34bn cash position is expected to fund completion of Phase 3, supporting a runway through key value inflection points despite high R&D burn.
Lilly's strong Q2, GLP-1 momentum and broad pipeline support growth, but valuation and rising competition remain key risks.
Structure Therapeutics advances aleniglipron, a potential best-in-class oral GLP-1, into Phase 3 for obesity, supported by strong Phase 2b data. GPCR's $1.5B cash position and a projected cash runway through 2028 underpin its ability to execute pivotal trials and commercial plans. My SOTP analysis yields a fair value of $42.49/share, with aleniglipron's risk-adjusted NPV at $1.34B and pipeline assets included at no additional cost.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on GPCR and any ticker you trade — then tracks every position and per-strategy win rate.
